TVM Capital
TVM Capital is a private equity and venture capital firm established in 1983 and headquartered in Munich, with offices across Europe, the United States, the Middle East and Asia. It provides early-stage through growth investments in life sciences, including biopharma, diagnostics, medtech, digital health, and in information and communications technology spanning software, semiconductors, telecommunications and related services. The firm typically invests between modest seven figures and low tens of millions of euros, often taking majority stakes in portfolio companies and supporting growth to market readiness, licensing, or global expansion. Exits are pursued through initial public offerings or sales to strategic buyers. The firm favors investments in Western markets, with attention to cross-border licenses and international collaboration.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Private Equity Round
neurocare
Private Equity Round in 2024
Neurocare Group is dedicated to enhancing mental health and performance through personalized therapy solutions. The company develops integrated equipment and a digital therapy platform that empowers clinicians to provide tailored treatment plans based on comprehensive assessments. By incorporating factors such as brain activity, sleep patterns, biomarkers, and other lifestyle metrics, Neurocare's platform facilitates individualized therapeutic programs. This approach leverages the principles of neuroplasticity, offering patients a measurable and effective clinical experience that supports their mental health needs. Through its innovative solutions, Neurocare aims to deliver best practices in neuroscience applications, contributing to improved mental well-being and performance.
Ixchelsis
Private Equity Round in 2013
Ixchelsis Ltd is a clinical-stage biotechnology company headquartered in Sandwich, United Kingdom, founded in 2011. The firm is focused on the development of IX-01, an oxytocin receptor antagonist aimed at treating premature ejaculation (PE). This innovative therapeutic approach represents a promising advancement in male sexual health. IX-01 has successfully completed a Phase 1 single ascending dose study in healthy male volunteers and is currently advancing toward clinical proof of concept. The company is supported by funding from prominent investors and is led by a skilled management team with significant experience in pharmaceutical research and development, particularly in the field of male reproductive health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.